VIRAX BIOLABS GROUP LTD (VRAX) Forecast, Price Target & Analyst Ratings

NASDAQ:VRAX • KYG9495L1251

Current stock price

0.1593 USD
-0.01 (-8.03%)
At close:
0.1594 USD
+0 (+0.06%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VIRAX BIOLABS GROUP LTD (VRAX).

Forecast Snapshot

Consensus Price Target

Price Target
$1.02
+ 540.30% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Dec 13, 2022
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.86%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$1.02
Upside
+ 540.30%
From current price of $0.16 to mean target of $1.02, Based on 7 analyst forecasts
Low
$1.01
Median
$1.02
High
$1.05

Price Target Revisions

1 Month
0.00%
3 Months
-95.00%

Price Target Summary

7 Wall Street analysts provided a forecast for the next 12 months for VRAX. The average price target is 1.02 USD. This implies a price increase of 540.3% is expected in the next year compared to the current price of 0.1593.
The average price target has been revised downward by 95% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

VRAX Current Analyst RatingVRAX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

VRAX Historical Analyst RatingsVRAX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -1 0 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.86%
VRAX was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about VRAX.
In the previous month the buy percentage consensus was at a similar level.
VRAX was analyzed by 7 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-01-09HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-31HC Wainwright & Co.Initiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Dec 13, 2022

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2032

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
Revenue
YoY % growth
VRAX revenue by date.VRAX revenue by date.
8.6K156.4K
1,718.60%		6.3K
-95.97%		13.762M
218,344.44%		4.08M
-70.35%		7.14M
75.00%		11.22M
57.14%		17.34M
54.55%		23.46M
35.29%		26.52M
13.04%
EBITDA
YoY % growth
VRAX ebitda by date.VRAX ebitda by date.
N/A-6.003M
-2.67%		-5.82M
3.06%		612.5K
110.52%		N/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
VRAX ebit by date.VRAX ebit by date.
-5.733M
-231.38%		-6.106M
-6.51%		-6.163M
-0.93%		612.5K
109.94%		N/AN/AN/AN/AN/AN/A
Operating Margin
VRAX operating margin by date.VRAX operating margin by date.
-66,660.47%-3,904.16%-97,823.81%4.45%N/AN/AN/AN/AN/AN/A
EPS
YoY % growth
VRAX eps by date.VRAX eps by date.
N/AN/A
-5.56%		N/A
68.42%		0.04
166.67%		N/AN/AN/AN/AN/AN/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

VRAX Yearly Revenue VS EstimatesVRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5M 10M 15M 20M 25M
VRAX Yearly EPS VS EstimatesVRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 0 -0.05 -0.1 -0.15

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
-4.67%
Revenue Next 5 Year
16.04%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

VIRAX BIOLABS GROUP LTD / VRAX Forecast FAQ

Can you provide the average price target for VIRAX BIOLABS GROUP LTD stock?

7 analysts have analysed VRAX and the average price target is 1.02 USD. This implies a price increase of 540.3% is expected in the next year compared to the current price of 0.1593.

What is the next earnings date for VRAX stock?

VIRAX BIOLABS GROUP LTD (VRAX) will report earnings on 2022-12-13, before the market open.

What is the consensus rating for VIRAX BIOLABS GROUP LTD (VRAX) stock?

The consensus rating for VIRAX BIOLABS GROUP LTD (VRAX) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.